Stockreport

Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023 [Yahoo! Finance]

Immunovant, Inc.  (IMVT) 
PDF Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two fiscal years Initial period 1 data from Phase 2b clinical trial of batoclimab in [Read more]